Incidence, Predictors, and Results of Acute Kidney Injury in Patients Undergoing TAVR

Acute kidney injury after transcatheter aortic valve replacement (TAVR) is a well-known adverse event for all interventional cardiologists. However, it has been understudied: only small observational research has been conducted, showing too wide incidence rates.

Incidencia, predictores y resultados de la injuria renal aguda en pacientes que reciben TAVI

This research included all patients who underwent TAVR in the USA between 2016 and 2018, totaling over 100,000 patients. All subjects had creatinine analysis done at baseline and after the procedure. Patients in hemodialysis were excluded.

A total of 11,566 patients (10.7%) suffered kidney injury after the procedure. The vast majority had grade 1 impairment, some presented grade 2, and 1212 (1.1% of the general population) had grade 3 injury.

Clinical factors associated with grade 3 (severe) kidney injury were high levels of creatinine, diabetes, cardiogenic shock, peripheral vascular disease, severe anemia, and African American heritage.

The procedural characteristics associated with grade 3 injury were non-elective procedure, crossover to conventional surgery, general anesthesia, use of inotropic drugs, use of self-expandable prosthesis, and contrast volume >100 milliliters.


Read also: Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight.


Mortality at one year among those who developed grade 1 kidney injury almost tripled that of those without kidney injury (hazard ratio [HR]: 2.7; 95% confidence interval [CI]: 2.5-2.8; p < 0.001), and in those with grade 3 injury, mortality was 7 times higher (HR: 7; 95% CI: 6.0-8.2; p < 0.001).

Conclusion

Using the STS/ACC database, acute kidney injury after TAVR has a 10.7% prevalence. Patients with grade 3 injury present 7x higher risk of one-year mortality than those without renal impairment.

Original title: Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement.

Reference: Howard M Julien et al. Circ Cardiovasc Interv. 2021 Apr;14(4):e010032. Doi: 10.1161/CIRCINTERVENTIONS.120.010032.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...